Skip to contentB
Bolt Biotherapeutics, Inc.
B
BOLTBolt Biotherapeutics, Inc. Released Aug 12, 2021, after the close
10-Q filed Aug 12, 2021, 43 days after period end · 0001564590-21-044002
Q2 2021 · 10-Q
Revenue$0.00$0.00−100.0% vs Q2 2020no prior Q1 2021 on file Net Income-$23.59M-$23.59M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bolt Biotherapeutics, Inc. · CIK 1641281 · Engraved from SEC EDGAR
N/M vs Q1 2021
EPS Diluted-$0.64-$0.64N/M vs Q2 2020N/M vs Q1 2021 Operating Income-$23,761,000N/M Operating Cash Flowderived-$3,986,000N/M Free Cash Flowderived-$4,689,000N/M ended Jun 30, 2021 · filed Aug 12, 2021 · 43 d after period end